DOA
AUPH icon

D'Orazio & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

D'Orazio & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Buy
+13,694
New +$219K 0.03% 268

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D'Orazio & Associates's AUPH Position: Q2 2026 in Review

D'Orazio & Associates opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 13,694 shares worth $232K. The stake represents 0.03% of the portfolio and ranks #268 among its holdings.

281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • D'Orazio & Associates held 13,694 shares of Aurinia Pharmaceuticals worth $232K as of Q2 2026.
  • Aurinia Pharmaceuticals was a new D'Orazio & Associates position in Q2 2026.
  • Aurinia Pharmaceuticals made up 0.03% of D'Orazio & Associates's portfolio in Q2 2026, its #268 holding.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.